2026-04-18T02:20:36Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/157662024-09-27T08:45:47Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Santos, Arnoldo author Martínez-Milla, Juan author Pérez-Calvo, César author Ibáñez, Borja author 2022-01-04 J Am Coll Cardiol. 2022 Jan 4;79(1):e13-e14 http://hdl.handle.net/20.500.12105/15766 34991793 10.1016/j.jacc.2021.10.030 1558-3597 Journal of the American College of Cardiology Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19.